Drugs / MOR107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03067363 | Feb → Mar 2017 | — | Alan Richardson | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOR107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03067363 ↗ |
| Action | Activate | “MOR107 is an angiotensin 2 receptor (AT2R) agonist” NCT03067363 ↗ |
| Route | Subcutaneous | “MOR107, single subcutaneous injection” NCT03067363 ↗ |